Format

Send to

Choose Destination
Transl Res. 2010 Sep;156(3):147-54. doi: 10.1016/j.trsl.2010.07.008. Epub 2010 Aug 1.

Pluripotent stem cell-derived natural killer cells for cancer therapy.

Author information

1
Department of Medicine and Stem Cell Institute, University of Minnesota, Minneapolis, MN 55455, USA.

Abstract

Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) provide an accessible, genetically tractable, and homogenous starting cell population to efficiently study human blood cell development. These cell populations provide platforms to develop new cell-based therapies to treat both malignant and nonmalignant hematological diseases. Our group previously demonstrated the ability of hESC-derived hematopoietic precursors to produce functional natural killer (NK) cells as well as an explanation of the underlying mechanism responsible for the inefficient development of T and B cells from hESCs. hESCs and iPSCs, which can be engineered reliably in vitro, provide an important new model system to study human lymphocyte development and produce enhanced cell-based therapies with the potential to serve as a "universal" source of antitumor lymphocytes. This review will focus on the application of hESC-derived NK cells with currently used and novel therapeutics for clinical trials, barriers to translation, and future applications through genetic engineering approaches.

PMID:
20801411
PMCID:
PMC2932648
DOI:
10.1016/j.trsl.2010.07.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center